How the Landscape Changed in 2025 and 2026 For roughly two years, compounded GLP-1s were widely available because the approved products were in shortage
Tirzepatide safety in human pregnancy remains unknown because controlled trials excluding pregnant participants are standard medical practice
This blog represents my honest assessment as a physician navigating this emerging space, with all its promise and its very real limitations
*In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)
With a wide range of causes, there is also a wide range of symptoms varying in degrees of severity
If no pathway is selected or multiple incompatible pathways are selected, the submission should be rejected/pended for correction